UK Approves Johnson & Johnson Oral Psoriasis Treatment
What happened
Johnson & Johnson received approval from the United Kingdom for its oral psoriasis treatment on October 24, 2026. The approval expands the company’s commercial opportunity in a major market and strengthens its immunology pipeline. Following the news, Johnson & Johnson's share price rose 3.8%.
From themarketsdaily.com
Why it matters
The approval strengthens Johnson & Johnson's position in the immunology market. The positive sentiment led to Johnson & Johnson's implied fair value being raised from $270.59 to $279.41 per share.
AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.
From themarketsdaily.com
Who's involved
- Johnson & JohnsonManufacturer of the approved oral psoriasis treatment
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AmundiSpeculative
Amundi might see increased investment attracted by Johnson & Johnson's strengthened valuation.
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer